KFDA granted sale of Symbicort Smart.

AstraZeneca Korea has received a KFDA approval for the sales of Symbicort (budesonide/formoterol), a combination of an inhaled corticosteroid and long-acting bronchodilator, for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD), which has shown to be a more effective treatment approach than traditional standard therapy, improving daily symptom control and reducing asthma ...